Pentamidine for the treatment of Pneumocystis carinii pneumonia and other protozoal diseases.
Pentamidine isethionate, discovered to have antiprotozoal activity in 1938, has recently been approved in the United States for the treatment of Pneumocystis carinii pneumonia. Despite frequent adverse reactions, which are at times life-threatening, pentamidine remains an important alternative to trimethoprim-sulfamethoxazole for the treatment of P. carinii pneumonia in patients with a history of allergy to sulfonamides or who have severe reactions or a lack of response to treatment with trimethoprim-sulfamethoxazole. Although not approved for other indications, pentamidine has been shown to be effective when used prophylactically against Trypanosoma brucei gambiense, the cause of West African sleeping sickness, as well as for treatment of the early hemolymphatic stage of that disease, and for treatment of some forms of leishmaniasis.
D000578:Amidines / Q000627:therapeutic use*; D006801:Humans; D007896:Leishmaniasis / Q000188:drug therapy; D010419:Pentamidine / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D011020:Pneumonia, Pneumocystis / Q000188:drug therapy*; D011528:Protozoan Infections / Q000188:drug therapy*; D014347:Trypanosoma brucei gambiense; D014353:Trypanosomiasis, African / Q000188:drug therapy
D000578:Amidines; D010419:Pentamidine